<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902020000100025</article-id>
<article-id pub-id-type="doi">10.29262/ram.v67i1.707</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Enfermedad renal crónica en adultos con inmunodeficiencias primarias en tratamiento con inmunoglobulina intravenosa]]></article-title>
<article-title xml:lang="en"><![CDATA[Chronic kidney disease in adults with primary immunodeficiency diseases in treatment with intravenous immunoglobulin]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[O&#8217;Farrill-Romanillos]]></surname>
<given-names><![CDATA[Patricia María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luna-Mújica]]></surname>
<given-names><![CDATA[Ramón Fabricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Contreras-García]]></surname>
<given-names><![CDATA[Carlos Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Anda]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Siglo XXI Hospital de Especialidades]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>67</volume>
<numero>1</numero>
<fpage>25</fpage>
<lpage>33</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902020000100025&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902020000100025&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902020000100025&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Antecedentes: La inmunoglobulina intravenosa es el tratamiento de elección para inmunodeficiencias primarias (IDP) humorales. Un tercio de los pacientes que reciben inmunoglobulina intravenosa presenta reacciones adversas, como nefrosis osmótica.  Objetivo: Evaluar la presencia de enfermedad renal en adultos con IDP humorales y en tratamiento con inmunoglobulina intravenosa.  Métodos: Estudio transversal, descriptivo y observacional de pacientes pertenecientes a la Clínica de Inmunodeficiencias Primarias del Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Ciudad de México, que reciben tratamiento con inmunoglobulina intravenosa. Se les aplicó un cuestionario con datos demográficos, depuración de creatinina en orina de 24 horas, creatinina sérica, urea y análisis de nitrógeno ureico en sangre.  Resultados: Se encuestó a 35 pacientes, 65.7 % fue del sexo femenino; la edad promedio fue de 34 años; 51.4 % presentó daño renal, con mayor frecuencia enfermedad renal crónica (55.6 %) cuando tenían más de cinco años de tratamiento con inmunoglobulina intravenosa, de acuerdo con la escala de la Kidney Disease Outcomes Quality Initiative.  Conclusiones: La enfermedad renal crónica se presenta en 51 % de los pacientes adultos con IDP en tratamiento con inmunoglobulina intravenosa por más de cinco años, por lo que esta población requiere evaluación periódica de la función renal y utilización de inmunoglobulina sin azúcares para reducir el riesgo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Background: Intravenous immunoglobulin (IVIG) is the treatment of choice for humoral primary immunodeficiency diseases (PIDs). A third of the patients who receive intravenous immunoglobulin have adverse reactions, such as osmotic nephrosis.  Objective: To assess the presence of kidney disease in adults with humoral PIDs, in treatment with intravenous immunoglobulin.  Methods: A cross-sectional, descriptive, and observational study of patients who belong to the PID Clinic of the Specialties Hospital of the National Medical Center &#8220;Siglo XXI&#8221;, Mexico City, who receive treatment with intravenous immunoglobulin. A questionnaire with demographic information, 24h urine creatinine clearance, serum creatinine, urea, and BUN (Blood Urea Nitrogen) was applied.  Results: 35 patients were surveyed; 65.7 % were women; the average age was 34 years; 51.4 % of the patients presented kidney damage. Those with &gt; 5 years of treatment with intravenous immunoglobulin presented chronic kidney disease (CKD) with more frequency (55.6 %) according to the KDOQI scale.  Conclusions: Chronic kidney disease occurs in 51 % of adult patients with PID who have been treated with intravenous immunoglobulin for more than 5 years; which is why these patients require periodic evaluations of their kidney function, and the use of sugar-free immunoglobulin in order to reduce the risk.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Inmunodeficiencia común variable]]></kwd>
<kwd lng="es"><![CDATA[Respuesta inmune humoral]]></kwd>
<kwd lng="es"><![CDATA[Inmunoglobulina intravenosa]]></kwd>
<kwd lng="es"><![CDATA[Falla renal crónica]]></kwd>
<kwd lng="en"><![CDATA[Common variable immunodeficiencies]]></kwd>
<kwd lng="en"><![CDATA[Humoral immune response]]></kwd>
<kwd lng="en"><![CDATA[Intravenous immunoglobulin]]></kwd>
<kwd lng="en"><![CDATA[Chronic renal failure]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Martínez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Rosales]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Padilla]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Martínez]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Blancas-Galicia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conceptos básicos de las inmunodeficiencias primarias]]></article-title>
<source><![CDATA[Rev Alerg Mex.]]></source>
<year>2016</year>
<volume>63</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>180-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bousfiha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jeddane]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Picard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ailal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bobby-Gaspar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Herz]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2017 IUIS phenotypic classification for primary immunodeficiencies]]></article-title>
<source><![CDATA[J Clin Immunol]]></source>
<year>2018</year>
<numero>38</numero>
<issue>38</issue>
<page-range>129-43</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rausell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What do primary immunodeficiencies tell us about the essentiality/redundancy of immune responses?]]></article-title>
<source><![CDATA[Semin Immunol]]></source>
<year>2018</year>
<numero>36</numero>
<issue>36</issue>
<page-range>13-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Srinivasa]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Alizadehfar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Desrosiers]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shuster]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pai]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Tsoukasa]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adult primary immune deficiency: What are we missing?]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2012</year>
<volume>125</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>779-86</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>European Society for Primary Immunodeficiencies</collab>
<source><![CDATA[ESID Registry-Working definitions for clinical diagnosis of PID]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Italia ]]></publisher-loc>
<publisher-name><![CDATA[ESID]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonilla]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Barlan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Costa-Carvalho]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham-Rundles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Rosales]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Consensus Document (ICON): Common variable immunodeficiency disorders]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2016</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-59</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aucouturier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mariault]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lacombe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Preud´homme]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of selective IgG subclass deficiency: A reappraisal]]></article-title>
<source><![CDATA[Clin Immunol Immunopathol]]></source>
<year>1992</year>
<volume>63</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>289-91</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrod]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical significance of IgG subclases]]></article-title>
<source><![CDATA[Curr Opin Pediatr]]></source>
<year>1993</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>696-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinosa-Rosales]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Berge&#769;s-Garci&#769;a]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coronado- Zarco]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Da&#769;vila-Gutie&#769;rrez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Faugier-Fuentes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Garci&#769;a-Campos]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consenso mexicano para la prescripción de inmunoglobulina G como tratamiento de reemplazo e inmunomodulación]]></article-title>
<source><![CDATA[Acta Pediatr Mex]]></source>
<year>2018</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>134-71</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical aspects of immunoglobulin replacement]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2017</year>
<volume>119</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>299-303</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orange]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Hossny]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Weiler]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Ballow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bonilla]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2006</year>
<volume>117</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
<page-range>S525-53</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goudouris]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Rego Silva]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Ouricuri]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Grumece]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Condino-Neto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Costa-Carvalho]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies]]></article-title>
<source><![CDATA[Einstein (Sao Paulo)]]></source>
<year>2017</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dantal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk]]></article-title>
<source><![CDATA[Am J Nephrol]]></source>
<year>2013</year>
<volume>38</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>275-84</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaveri]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Lecerf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saha]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kazatchkine]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Lacroix-Desmazes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bayry]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous immunoglobulin and immune response]]></article-title>
<source><![CDATA[Clin Exp Immunol]]></source>
<year>2014</year>
<volume>178</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>94-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects of immunoglobulin therapy]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>1299</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caress]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Eickman]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of intravenous immunoglobulin treatment]]></article-title>
<source><![CDATA[Expert Opin. Drug Saf]]></source>
<year>2010</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>971-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marie]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cherin]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Michaellet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pelus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dantal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Crave]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of adverse effects related to human immunoglobulin therapy: recommendations for clinical practice]]></article-title>
<source><![CDATA[Rev Med Interne]]></source>
<year>2017</year>
<volume>38</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>312-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Saperstein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal and hematologic side effects of long-term intravenous immunoglobulin therapy in patients with neurologic disorders]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2017</year>
<volume>56</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1173-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[RY]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Baez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bhargave]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous gammaglobulin-associated renal impairment reported to FDA: 2004-2009]]></article-title>
<source><![CDATA[Clin Nephrol]]></source>
<year>2011</year>
<volume>76</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>365-72</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Mireles]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Galguera-Sauceda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gaspar-López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López-Rocha]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Campos-Romero]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[del Rivero-Hernández]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos adversos de la aplicación ambulatoria de inmunoglobulina intravenosa en adultos con inmunodeficiencia común variable]]></article-title>
<source><![CDATA[Rev Alerg Mex]]></source>
<year>2014</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>131-40</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaspar-López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda-Novales]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[López-Rocha]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Mireles]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Segura-Méndez]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimación de la tasa de filtración glomerular en adultos con inmunodeficiencia común variable tratados con inmunoglobulina intravenosa. ¿Qué fórmula utilizar?]]></article-title>
<source><![CDATA[Rev Alerg Mex]]></source>
<year>2014</year>
<volume>61</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>45-51</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Bilous]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Coresh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de Francisco]]></surname>
<given-names><![CDATA[ALM]]></given-names>
</name>
<name>
<surname><![CDATA[Griffith]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Kidney disease: Improving Global Outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease]]></article-title>
<source><![CDATA[Kidney Int Suppl]]></source>
<year>2013</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-150</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
